JP2011500718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500718A5 JP2011500718A5 JP2010530124A JP2010530124A JP2011500718A5 JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5 JP 2010530124 A JP2010530124 A JP 2010530124A JP 2010530124 A JP2010530124 A JP 2010530124A JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5
- Authority
- JP
- Japan
- Prior art keywords
- mva
- antigen
- polypeptide
- pap
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 61
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 229940123237 Taxane Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 13
- 101001035654 Homo sapiens 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 claims description 12
- 101000785915 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 Proteins 0.000 claims description 12
- 101000735427 Homo sapiens Poly(A) RNA polymerase, mitochondrial Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 230000002476 tumorcidal effect Effects 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 claims description 9
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 8
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 230000037452 priming Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 108091029795 Intergenic region Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 claims description 2
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96089307P | 2007-10-18 | 2007-10-18 | |
| US60/960,893 | 2007-10-18 | ||
| PCT/US2008/080229 WO2009052328A1 (en) | 2007-10-18 | 2008-10-16 | Use of mva to treat prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500718A JP2011500718A (ja) | 2011-01-06 |
| JP2011500718A5 true JP2011500718A5 (cg-RX-API-DMAC7.html) | 2011-10-20 |
| JP5669581B2 JP5669581B2 (ja) | 2015-02-12 |
Family
ID=40342626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530124A Expired - Fee Related JP5669581B2 (ja) | 2007-10-18 | 2008-10-16 | 前立腺癌を処置するためのｍｖａの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7867483B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2207564B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5669581B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101648087B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101888853B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008312444B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2702586C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2207564T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2608604T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL204541A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ584042A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2499606C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009052328A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| PT1335987E (pt) * | 2000-11-23 | 2006-05-31 | Bavarian Nordic As | Variante do virus vacina modificado ancara |
| JP2009531324A (ja) | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体 |
| US8940298B2 (en) * | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| EP2209498A2 (en) * | 2007-10-03 | 2010-07-28 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| EP2207564B1 (en) * | 2007-10-18 | 2016-10-05 | Bavarian Nordic A/S | Use of mva to treat prostate cancer |
| US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| GB2484058A (en) * | 2009-12-01 | 2012-04-04 | Uni Konstanz | Prostate cancer DNA vaccine |
| BR112012012887A2 (pt) | 2009-12-02 | 2017-05-02 | Imaginab Inc | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. |
| JP6312141B2 (ja) | 2012-03-30 | 2018-04-18 | 国立大学法人京都大学 | 前立腺がん検査用尿中バイオマーカー |
| MX2016005656A (es) * | 2013-11-01 | 2016-07-14 | Pfizer | Vectores para expresion de antigenos asociados a prostata. |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| CA2977660A1 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| JP6936153B2 (ja) | 2015-04-17 | 2021-09-15 | メモリアル スローン ケタリング キャンサー センター | Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用 |
| MX2018001566A (es) | 2015-08-07 | 2019-04-25 | Imaginab Inc | Construcciones de union a antigeno para moleculas diana. |
| CA3000275A1 (en) * | 2015-10-02 | 2017-04-06 | University Of Copenhagen | Small molecules blocking histone reader domains |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN108883203A (zh) * | 2016-02-12 | 2018-11-23 | 麦迪逊疫苗公司 | 癌症疗法 |
| AU2017222686B2 (en) | 2016-02-25 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| EP3419662A4 (en) | 2016-02-25 | 2019-09-18 | Memorial Sloan Kettering Cancer Center | HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS |
| CA3021947A1 (en) * | 2016-04-26 | 2017-11-02 | Sumitomo Dainippon Pharma Co., Ltd. | Substituted purine derivative |
| RS66700B1 (sr) | 2016-06-03 | 2025-05-30 | Regeneron Pharma | Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu |
| SG11201810631SA (en) * | 2016-06-03 | 2018-12-28 | Etubics Corp | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| CN106084027A (zh) * | 2016-06-24 | 2016-11-09 | 安徽未名细胞治疗有限公司 | 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用 |
| CN106119231A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种肿瘤抗原psa的ctl识别表位肽及其应用 |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| US10925947B2 (en) * | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| JP7480126B2 (ja) | 2018-09-15 | 2024-05-09 | メモリアル スローン ケタリング キャンサー センター | がん免疫療法のための、組換えポックスウイルス |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020247859A2 (en) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| MX2022005980A (es) | 2019-11-18 | 2022-09-07 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos. |
| JP2023521194A (ja) * | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用 |
| US12295997B2 (en) * | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3939746B2 (ja) * | 1991-07-25 | 2007-07-04 | バイオジェン・アイデック・インコーポレイテッド | 細胞毒性ｔ−リンパ球応答の誘導 |
| JPH09504000A (ja) * | 1993-08-11 | 1997-04-22 | ジェナー テクノロジーズ | 前立腺癌ワクチン |
| US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US6165460A (en) * | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| WO1998004689A1 (en) * | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| CA2286477A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| ES2222728T3 (es) | 1998-10-05 | 2005-02-01 | Pharmexa A/S | Procedimiento de vacunacion terapeutica. |
| CA2354024C (en) * | 1998-12-09 | 2009-12-22 | Jeffrey Schlom | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| PT1335987E (pt) | 2000-11-23 | 2006-05-31 | Bavarian Nordic As | Variante do virus vacina modificado ancara |
| WO2003073828A2 (en) * | 2002-03-01 | 2003-09-12 | Applied Immune Technologies | Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens |
| MXPA04011194A (es) * | 2002-05-16 | 2005-02-14 | Bavarian Nordic As | Virus de viruela recombinantes que expresan los genes homologos introducidos dentro del genoma viral de la viruela. |
| WO2005019464A1 (en) * | 2003-08-21 | 2005-03-03 | Virax Development Pty Ltd | Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer |
| BRPI0401465A (pt) | 2004-04-20 | 2006-02-21 | Embria Informatica Ltda | sistema para administrar interações entre usuários e aplicações de software em um ambiente web |
| EP2207564B1 (en) | 2007-10-18 | 2016-10-05 | Bavarian Nordic A/S | Use of mva to treat prostate cancer |
-
2008
- 2008-10-16 EP EP08839145.3A patent/EP2207564B1/en not_active Not-in-force
- 2008-10-16 KR KR1020107010873A patent/KR101648087B1/ko not_active Expired - Fee Related
- 2008-10-16 NZ NZ584042A patent/NZ584042A/xx not_active IP Right Cessation
- 2008-10-16 NZ NZ601827A patent/NZ601827A/en not_active IP Right Cessation
- 2008-10-16 DK DK08839145.3T patent/DK2207564T3/en active
- 2008-10-16 US US12/253,094 patent/US7867483B2/en not_active Expired - Fee Related
- 2008-10-16 RU RU2010115220/15A patent/RU2499606C2/ru not_active IP Right Cessation
- 2008-10-16 KR KR1020167013629A patent/KR20160065985A/ko not_active Ceased
- 2008-10-16 AU AU2008312444A patent/AU2008312444B2/en not_active Ceased
- 2008-10-16 CN CN2008801193517A patent/CN101888853B/zh not_active Expired - Fee Related
- 2008-10-16 JP JP2010530124A patent/JP5669581B2/ja not_active Expired - Fee Related
- 2008-10-16 CA CA2702586A patent/CA2702586C/en not_active Expired - Fee Related
- 2008-10-16 ES ES08839145.3T patent/ES2608604T3/es active Active
- 2008-10-16 WO PCT/US2008/080229 patent/WO2009052328A1/en not_active Ceased
-
2010
- 2010-03-16 IL IL204541A patent/IL204541A/en active IP Right Grant
- 2010-08-30 US US12/871,017 patent/US8377688B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500718A5 (cg-RX-API-DMAC7.html) | ||
| Moore et al. | Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria | |
| Verardi et al. | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| EP2958994B1 (en) | Vaccine composition | |
| US9707285B2 (en) | Vaccination methods | |
| RU2010115220A (ru) | Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты | |
| Webster et al. | Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers | |
| WO2015106697A1 (zh) | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 | |
| JP2020528911A5 (cg-RX-API-DMAC7.html) | ||
| WO2014063601A1 (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| US8734806B2 (en) | Immunogenic composition and use thereof | |
| JP2018517419A5 (cg-RX-API-DMAC7.html) | ||
| Bubenik et al. | Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| JP2014139185A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Optimisation of prime–boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine | |
| Marcos-Villar et al. | Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium | |
| Iampietro et al. | Immunogenicity and cross-reactivity of rhesus adenoviral vectors | |
| Ren et al. | Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination | |
| JP7454320B2 (ja) | アジュバントとしての腫瘍溶解性ウイルス | |
| Ding et al. | Evaluation of tumor specificity and immunity of thymidine kinase-deleted vaccinia virus guang9 strain | |
| Yang et al. | Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity | |
| CN1887350A (zh) | 一种重组疫苗及其用途 |